Regulators’ concerns about potential contamination of OTC eye care products due to manufacturing-quality deficiencies aren’t limited to an Indian firm linked to artificial tear drops found to contain bacterial contamination not previously seen in the US.
The Food and Drug Administration has warned two US drug firms providing OTC eye drops about failing to maintain sanitary conditions since announcing early in 2023 that Indian firm Global Pharma Healthcare Private Ltd
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?